601 related articles for article (PubMed ID: 19133988)
1. Nuclear receptors as therapeutic targets in cholestatic liver diseases.
Zollner G; Trauner M
Br J Pharmacol; 2009 Jan; 156(1):7-27. PubMed ID: 19133988
[TBL] [Abstract][Full Text] [Related]
2. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations.
Zollner G; Marschall HU; Wagner M; Trauner M
Mol Pharm; 2006; 3(3):231-51. PubMed ID: 16749856
[TBL] [Abstract][Full Text] [Related]
3. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
4. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury.
Stedman CA; Liddle C; Coulter SA; Sonoda J; Alvarez JG; Moore DD; Evans RM; Downes M
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2063-8. PubMed ID: 15684063
[TBL] [Abstract][Full Text] [Related]
5. Nuclear receptors as drug targets in cholestatic liver diseases.
Halilbasic E; Baghdasaryan A; Trauner M
Clin Liver Dis; 2013 May; 17(2):161-89. PubMed ID: 23540496
[TBL] [Abstract][Full Text] [Related]
6. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.
Wagner M; Halilbasic E; Marschall HU; Zollner G; Fickert P; Langner C; Zatloukal K; Denk H; Trauner M
Hepatology; 2005 Aug; 42(2):420-30. PubMed ID: 15986414
[TBL] [Abstract][Full Text] [Related]
7. Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders.
Molinaro A; Marschall HU
Biochem Soc Trans; 2022 Feb; 50(1):361-373. PubMed ID: 35191955
[TBL] [Abstract][Full Text] [Related]
8. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis.
Trauner M; Wagner M; Fickert P; Zollner G
J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S111-24. PubMed ID: 15758646
[TBL] [Abstract][Full Text] [Related]
9. Effects of Yinzhihuang on Alleviating Cyclosporine A-Induced Cholestatic Liver Injury via Farnesoid X Receptor-Mediated Regulation of Transporters and Enzymes in Vitro and in Vivo.
Qin Y; Tan J; Han X; Wang N; Zhai X; Lu Y
Biol Pharm Bull; 2023; 46(12):1810-1819. PubMed ID: 38044100
[TBL] [Abstract][Full Text] [Related]
10. Nuclear receptor ligands in therapy of cholestatic liver disease.
Sturm E; Wagner M; Trauner M
Front Biosci (Landmark Ed); 2009 Jan; 14(11):4299-325. PubMed ID: 19273351
[TBL] [Abstract][Full Text] [Related]
11. Xenobiotic-sensing nuclear receptors CAR and PXR as drug targets in cholestatic liver disease.
Kakizaki S; Takizawa D; Tojima H; Yamazaki Y; Mori M
Curr Drug Targets; 2009 Nov; 10(11):1156-1163. PubMed ID: 19925451
[TBL] [Abstract][Full Text] [Related]
12. Hesperidin alleviates cholestasis via activation of the farnesoid X receptor in vitro and in vivo.
Zhang G; Sun X; Wen Y; Shi A; Zhang J; Wei Y; Wu X
Eur J Pharmacol; 2020 Oct; 885():173498. PubMed ID: 32841642
[TBL] [Abstract][Full Text] [Related]
13. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.
Panzitt K; Jungwirth E; Krones E; Lee JM; Pollheimer M; Thallinger GG; Kolb-Lenz D; Xiao R; Thorell A; Trauner M; Fickert P; Marschall HU; Moore DD; Wagner M
J Hepatol; 2020 Jun; 72(6):1122-1131. PubMed ID: 32001325
[TBL] [Abstract][Full Text] [Related]
14. FXR and PXR: potential therapeutic targets in cholestasis.
Jonker JW; Liddle C; Downes M
J Steroid Biochem Mol Biol; 2012 Jul; 130(3-5):147-58. PubMed ID: 21801835
[TBL] [Abstract][Full Text] [Related]
15. Role of farnesoid X receptor in cholestasis.
Yuan ZQ; Li KW
J Dig Dis; 2016 Aug; 17(8):501-509. PubMed ID: 27383832
[TBL] [Abstract][Full Text] [Related]
16. Lignans from Schisandra sphenanthera protect against lithocholic acid-induced cholestasis by pregnane X receptor activation in mice.
Fan S; Liu C; Jiang Y; Gao Y; Chen Y; Fu K; Yao X; Huang M; Bi H
J Ethnopharmacol; 2019 Dec; 245():112103. PubMed ID: 31336134
[TBL] [Abstract][Full Text] [Related]
17. β-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids
Klag T; Thomas M; Ehmann D; Courth L; Mailänder-Sanchez D; Weiss TS; Dayoub R; Abshagen K; Vollmar B; Thasler WE; Stange EF; Berg CP; Malek NP; Zanger UM; Wehkamp J
Front Immunol; 2018; 9():1735. PubMed ID: 30100908
[TBL] [Abstract][Full Text] [Related]
18. Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis.
Stahl S; Davies MR; Cook DI; Graham MJ
Xenobiotica; 2008 Jul; 38(7-8):725-77. PubMed ID: 18668429
[TBL] [Abstract][Full Text] [Related]
19. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
20. [FXR modulators and cholestatic diseases.].
Alvaro D; Bragazzi MC; Venere R; Ridola L
Recenti Prog Med; 2021 Feb; 112(2):124-127. PubMed ID: 33624625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
